Nasus Pharma (NSRX) Current Leases (2025)

Nasus Pharma (NSRX) posted Current Leases of $45000.0 for Q4 2025.

Nasus Pharma (NSRX) Current Leases (2025) Analysis & Trends

Nasus Pharma (NSRX) has reported Current Leases for 1 consecutive years, with $45000.0 the latest figure, recorded in Q4 2025.

  • Current Leases for Q4 2025 came in at $45000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $45000.0 (changed N/A YoY), and the FY2025 annual result was $45000.0, changed N/A from the prior year.
  • Current Leases was $45000.0 for Q4 2025 at Nasus Pharma.
  • Over five years, Current Leases peaked at $45000.0 in Q4 2025 and troughed at $45000.0 in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Current Leases (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn -
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn -
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn -
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn -
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn -
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn -
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn -
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn -
9 Novartis Ag 113.45 Bn 113.67 Bn - 271.00 Mn
10 Nasus Pharma 28.20 Mn 23.91 Mn - 45,000.00

Historic Data

Download Data
DateValue
Dec 31, 2025 45,000.00